Frontier IP Group plc New Portfolio Company - The Vaccine Group
August 08 2017 - 2:01AM
RNS Non-Regulatory
TIDMFIPP
Frontier IP Group plc
08 August 2017
Reach
AIM: FIPP
8 August 2017
Frontier IP Group Plc
("Frontier IP" or the "Group")
New Portfolio Company - The Vaccine Group
Frontier IP, which specialises in the commercialisation of
intellectual property, is pleased to announce that it has received
a 21% equity stake in The Vaccine Group Limited ("The Vaccine Group
"), a spinout company from the University of Plymouth.
Governments, pharmaceutical companies and supranational bodies
are showing increasing concern about emerging infectious diseases.
The Vaccine Group will exploit technology developed by Dr Michael
Jarvis, Associate Professor in Virology and Immunology at the
University of Plymouth, who specialises in the creative design of
herpesvirus-based vaccines for the control of disease.
The Vaccine Group aims to commercialise novel vaccine platforms
for the development of vaccines for use in infection control (such
as bovine tuberculosis) and for a rapid response to pathogens which
unpredictably cross the species barrier and pose a significant
threat to human health. Target pathogens include avian influenza A,
Ebola and Marburg viruses, MERS and SARS coronaviruses and Rift
Valley fever virus.
Dr Jarvis' work has previously received funding from a number of
sources, including UK Innovate, National Institutes of Health and
the Medical Research Council. Initial work in The Vaccine Group
will focus on herpesvirus-based platforms suitable for use in
animals, to protect human health by targeting the animal species
from which disease is transmitted to humans, for vaccination
(termed zoonoses barrier vaccines). Future developments will
include vaccines for use in humans.
Frontier IP's role will be to provide commercialisation
services, industry expertise and strong links to the pharmaceutical
industry. Paul Mantle, a Portfolio Executive at Frontier IP, is a
director of The Vaccine Group and brings wide industrial experience
of commercialising new technology.
Neil Crabb, Chief Executive of Frontier IP, said: "We are
delighted to support development of The Vaccine Group. Emerging
Infectious Diseases are a growing threat to economies and to the
global population. A rapid response vaccine platform will be a
valuable addition to current management strategies and a critical
resource when new diseases emerge."
Dr Michael Jarvis, Chief Scientific Officer of The Vaccine
Group, said: "My laboratory has nearly 20 years' experience in the
development of vaccines based on herpesvirus-based technology.
Science is a collaborative endeavour, and The Vaccine Group
provides a new vehicle by which we can interact with fellow
scientists, industry and investors to prevent emergence of
infectious diseases relevant to global human health and
agriculture."
ENDS
For further information:
Frontier IP Group Plc T: 0131 240 1251
Neil Crabb, Chief Executive
Company website: www.frontierip.co.uk
Cenkos Securities plc (Nominated T: 0131 220 6939
Adviser and Joint Broker)
Neil McDonald / Beth McKiernan
Peterhouse Corporate Finance T: 020 7469 0935
Limited (Joint Broker)
Lucy Williams
Kreab (Financial PR) T: 020 7074 1800
Robert Speed / Matthew Jervois
University of Plymouth T: 01884 38346
Andrew Gould
Notes to Editor:
About Frontier IP Group plc
www.frontierip.co.uk.
Frontier IP specialises in assisting institutions and companies
in the commercialisation and exploitation of their intellectual
property. It establishes formal and informal relationships with
sources of exploitable IP, principally universities. Its core
business is building and growing a portfolio of equity stakes in
spin-out companies by taking an active involvement in the
commercialisation and funding of these businesses.
About Dr Michael A Jarvis
www.thejarvislab.com
Dr Jarvis's main scientific interest is in the creative design
of herpesvirus-based vaccines for the control of disease. A main
area of work is the control of infectious pathogens at the
animal:human interface - with a particular focus on decreasing
zoonotic (animal to human) microbe transmission with the use of
Zoonoses Blocking Vaccines. The Jarvis Laboratory has multiple
collaborative projects funded by UK Innovate and the MRC as well as
agricultural interest organizations investigating aspects of basic
and applied herpesvirus-based vaccine technology.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAUGUQWRUPMGBM
(END) Dow Jones Newswires
August 08, 2017 02:01 ET (06:01 GMT)
Frontier Ip (LSE:FIPP)
Historical Stock Chart
From Apr 2024 to May 2024
Frontier Ip (LSE:FIPP)
Historical Stock Chart
From May 2023 to May 2024